A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells
Authors:
- 28 August 2001
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (18) , 10332-10337
Abstract
Pancreatic cancer is an extremely aggressive neoplasm whose incidence equals its death rate. Despite intensive analysis, the genetic changes that mediate pancreatic cancer development and effective therapies for diminishing the morbidity associated with this disease remain unresolved. Through subtraction hybridization, we have identified a gene associated with induction of irreversible growth arrest, cancer reversion, and terminal differentiation in human melanoma cells, melanoma differentiation associated gene-7 ( mda- 7). Ectopic expression of mda- 7 when using a recombinant adenovirus, Ad. mda- 7, results in growth suppression and apoptosis in a broad spectrum of human cancers with diverse genetic defects, without exerting deleterious effects in normal human epithelial or fibroblast cells. Despite the apparently ubiquitous antitumor effects of mda- 7, pancreatic carcinoma cells are remarkably refractory to Ad. mda -7 induced growth suppression and apoptosis. In contrast, the combination of Ad. mda- 7 with antisense phosphorothioate oligonucleotides, which target the K-ras oncogene (a gene that is mutated in 85 to 95% of pancreatic carcinomas), induces a dramatic suppression in growth and a decrease in cell viability by induction of apoptosis. In mutant K- ras pancreatic carcinoma cells, programmed cell death correlates with expression and an increase, respectively, in MDA -7 and BAX proteins and increases in the ratio of BAX to BCL- 2 proteins. Moreover, transfection of mutant K- ras pancreatic carcinoma cells with an antisense K- ras expression vector and infection with Ad. mda- 7 inhibits colony formation in vitro and tumorigenesis in vivo in nude mice. These intriguing observations demonstrate that a combinatorial approach, consisting of a cancer-specific apoptosis-inducing gene and an oncogene inactivation strategy, may provide the foundation for developing an effective therapy for pancreatic cancer.Keywords
This publication has 46 references indexed in Scilit:
- Mechanisms of ApoptosisThe American Journal of Pathology, 2000
- Regional chemotherapy in the treatment of advanced pancreatic cancer — is it relevant?European Journal of Cancer, 2000
- PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RASOncogene, 2000
- Pancreatic CancerDrugs, 2000
- The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude miceGene Therapy, 2000
- What Is the True Rate of K-ras Mutation in Carcinoma of the Pancreas?Pancreas, 1998
- The Molecular and Cellular Biology of Pancreatic CancerCritical Reviews™ in Eukaryotic Gene Expression, 1998
- Phosphorothioate antisense oligodeoxynucleotides: questions of specificityTrends in Biotechnology, 1996
- Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras geneAnti-Cancer Drugs, 1995
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesCell, 1988